1、We measured the plasminogen content and plasmin activity in 54 leukemic patients.
對54例白血病患者進行血漿纖溶酶原(plg)及纖溶酶(PL)活性測定。

2、Expression of plasminogen activator in human bladder cancer
纖溶酶原激活物在膀胱移行細胞癌中的表達及其意義

3、Plasminogen activator inhibitor-1 is the main regulator of the fibrinolytic system.
血漿纖溶酶原激活物抑制劑(PAI) - 1是纖溶系統(tǒng)的主要調(diào)控因子。

4、Urokinase, a human plasminogen activator, is used clinically to promote the dissolution of thrombi.
尿激酶是一種纖溶酶原激活劑，臨床上用于治療血栓。

5、Conclusion The plasminogen ability is lower in women with PCOS.
結論PCOS患者的血纖溶能力較正常對照者有所下降。

plasminogen翻譯